MRI assessment for beta-blockers in portal hypertensio

Completed

• Conditions: Portal hypertension; Circulatory System

• Registration Number: ISRCTN98001632
• Lead Sponsor: niversity of Edinburgh/ACCORD

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-05-19
• Last Update Posted: 28 August 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Male or female patients aged 18-80 with liver cirrhosis
2. Portal hypertension in whom commencement of beta-blockers is clinically indicated

Exclusion Criteria

1. Contraindication to Beta-Blocker therapy (such as moderate to severe asthma)
2. Contraindication to MRI scan
3. Contraindication to administration of gadolinium-based MRI contrast (including eGFR <30mL/min)
4. Concomitant use of other vasoactive drugs (e.g. nitrates, phosphodiesterase inhibitors)
5. Previous TIPSS insertion
6. Portal vein thrombosis
7. Hepatocellular carcinoma
8. Pregnancy or breastfeeding
9. Inability to obtain informed consent (e.g. refusal/overt hepatic encephalopathy)

Study & Design

• Study Type: Interventional
• Study Design: Not specified